EUVIMEDEUVIMED entdecken
Fallbericht

Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia

Fumihiko Ouchi, Naoki Shingai, Yuho Najima, Daichi Sadato, Chizuko Hirama, Satoshi Wakita, Kaori Kondo, Yasutaka Sadaga, Chika Kato, Satoshi Sakai, Yasuhiro Kambara, Masashi Shimabukuro und 10 weitere

International Journal of Hematology · 2025

DOI: 10.1007/s12185-024-03863-4 ↗

Kurz gefasst

Fallbericht in der Zeitschrift International Journal of Hematology, 2025. Verfasst von Fumihiko Ouchi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-8-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Jap…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Benzothiazoles, fms-Like Tyrosine Kinase 3, Lymphocyte Transfusion. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: the Clinical Research Fund of the Tokyo Metropolitan Hospital Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukemia (AML) has a poor prognosis, particularly with DNMT3A and NPM1 mutations. Quizartinib, a FLT3 inhibitor showing clinical benefit in FLT3-ITD-positive AML, has unclear safety and efficacy when combined with donor lymphocyte infusion (DLI). We report a case of FLT3-ITD-positive AML with DNMT3A and NPM1 mutations that relapsed after allogeneic hematopoietic stem cell transplantation (allo-HCT) and was treated with quizartinib and DLI. A 49-year-old man was diagnosed with AML. Target-sequencing analysis of the bone marrow revealed FLT3-ITD, DNMT3A R882, and NPM1 mutations. Although the patient achieved complete remission (CR) through induction therapy and received allo-HCT, he relapsed on day 71. Quizartinib was initiated on day 79, and the patient achieved CR with incomplete recovery on day 106. He did not desire a second allo-HCT and continued quizartinib in combination with DLI, which was started on day 156 and administered eight times every 2 to 3 months. The patient achieved hematological CR on day 163 and remained in molecular CR 3 years after allo-HCT without adverse effects. Quizartinib combined with DLI may be a feasible treatment for early relapse of FLT3-ITD-positive AML after allo-HCT, even with concurrent DNMT3A and NPM1 mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteBenzothiazolesfms-Like Tyrosine Kinase 3Lymphocyte TransfusionPhenylurea CompoundsHumansMaleMiddle AgedNucleophosminHematopoietic Stem Cell TransplantationRecurrenceMutationDNA Methyltransferase 3ADNA (Cytosine-5-)-MethyltransferasesTandem Repeat SequencesTransplantation, Homologous

Stichwörter der Autor:innen

FLT3-ITDAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationDonor lymphocyte infusionQuizartinib

Substanzen

BenzothiazolesNucleophosminfms-Like Tyrosine Kinase 3NPM1 protein, humanPhenylurea CompoundsquizartinibFLT3 protein, humanDNA Methyltransferase 3ADNMT3A protein, humanDNA (Cytosine-5-)-Methyltransferases

Autor:innen und Institutionen

  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-8-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-8-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan. yuhonajima@gmail.com.
  • Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Hematology, Nippon Medical School, Tokyo, Japan.
  • Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Laboratory of Oncology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.

Förderung

  • the Clinical Research Fund of the Tokyo Metropolitan Hospital Organization

Zitieren

APA

Ouchi, F., Shingai, N., Najima, Y., Sadato, D., Hirama, C., Wakita, S., Kondo, K., Sadaga, Y., Kato, C., Sakai, S., Kambara, Y., Shimabukuro, M., Inai, K., Toya, T., Shimizu, H., Haraguchi, K., Kobayashi, T., Harada, H., Okuyama, Y., …, & Doki, N. (2025). Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03863-4

Vancouver

Ouchi F, Shingai N, Najima Y, Sadato D, Hirama C, Wakita S, et al. Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia. International Journal of Hematology. 2025. doi:10.1007/s12185-024-03863-4

BibTeX
@article{Ouchi2025,
  author = {Ouchi, Fumihiko and Shingai, Naoki and Najima, Yuho and Sadato, Daichi and Hirama, Chizuko and Wakita, Satoshi and Kondo, Kaori and Sadaga, Yasutaka and Kato, Chika and Sakai, Satoshi and Kambara, Yasuhiro and Shimabukuro, Masashi and Inai, Kazuki and Toya, Takashi and Shimizu, Hiroaki and Haraguchi, Kyoko and Kobayashi, Takeshi and Harada, Hironori and Okuyama, Yoshiki and Yamaguchi, Hiroki and Harada, Yuka and Doki, Noriko},
  title = {Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia},
  journal = {International Journal of Hematology},
  year = {2025},
  doi = {10.1007/s12185-024-03863-4}
}
Kostenlos starten →